Individuals with psychiatric disorders tend to have excessive morbidity. They typically have
high rates of respiratory illnesses, infectious diseases, substance abuse (including …

Objective Relapse and acute exacerbation are common in schizophrenia and may impact
treatment response and outcome. Evidence is conflicting in respect to superiority of long …

Background: Truly effective treatments for schizophrenia require much more than clinical
efficacy. Symptom improvement is all that is required to demonstrate clinical efficacy …

Controlled research trials have shown that atypical antipsychotics have important
advantages over standard antipsychotics, including a broader spectrum of efficacy and …

Background: Weight gain is a side effect of therapy with many atypical antipsychotics and
may have important clinical repercussions with respect to long-term health and treatment …

Background: The long-term safety and efficacy of long-acting injectable risperidone, the first
long-acting second-generation antipsychotic, were evaluated in stable patients with …

Few controlled trials compared second-generation antipsychotics (SGAs) with first-
generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We …

The treatment of schizophrenia changed drastically with the discovery of antipsychotic
medications in the 1950s, the release of clozapine in the US in 1989 and the subsequent …

BACKGROUND: Recently, the “Remission in Schizophrenia Working Group” proposed
remission criteria consisting of a reduction to mild levels on key symptoms for at least 6 …

Social dysfunction is a hallmark of schizophrenia. Social isolation may increase individuals'
risk for psychotic symptom exacerbation and relapse. Monitoring and timely detection of …